Direct targeting of the nucleocapsid protein by morin inhibits Hantaan virus infection.

Hantaan virus (HTNV), a major etiologic agent of hemorrhagic fever with renal syndrome (HFRS), poses a significant threat to global public health. Currently, there are no clinically approved antiviral drugs specifically for HTNV infection, nor are there any highly effective preventive vaccines. Thus, the development of effective therapeutic strategies is critically important. This study investigated the antiviral efficacy of morin against HTNV and its potential mechanism of action using in vitro assays. Our results demonstrate that morin inhibits HTNV infection in a concentration-dependent manner and primarily targets the post-entry replication stage of the viral life cycle. Further mechanistic studies revealed that morin exerts its antiviral effects by directly interacting with the HTNV nucleocapsid protein (NP). In conclusion, this study identifies morin as a promising candidate for anti-HTNV drug development, providing a new strategic direction for HFRS treatment.